Industry Focus

Amgen's $13.4 billion cash offer has won the bidding war for Celgene and Bristol-Myers Squibb's psoriasis drug, Otezla. Here's why the Goliath biopharma is betting so big on its success. Also, new data from The Medicines Company suggests a new cholesterol-busting drug is on it's way to approval. Stocks: CELG, BMY, AMGN, MDCO

Check out more of our content here:

Direct download: 20190904_IF_Healthcare.mp3
Category:Podcast -- posted at: 3:30pm EST